Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Mar 13, 2025
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases
- Lead target and indication to be announced MY 2025
NASDAQ:GBIO (9/12/2025, 8:00:01 PM)
5.93
-0.08 (-1.33%)
Find more stocks in the Stock Screener
